Innovative Diagnostic Expansion Quest Diagnostics is actively expanding its diagnostic testing capabilities, exemplified by the recent launch of advanced pharmacogenomic laboratory tests and Broadening access to molecular residual disease (MRD) tests. These innovations provide opportunities to partner with healthcare providers and pharmaceutical companies seeking cutting-edge diagnostic solutions.

Strategic Service Repositioning The company has recently closed and reestablished offices, such as in Keene, New Hampshire, indicating a focus on optimizing service locations and operational efficiency. This approach suggests potential upsell opportunities in adjacent regions or through enhanced local laboratory services.

Industry Engagement & Thought Leadership Participation in major healthcare conferences and events like the Baird 2025 Global Healthcare Conference highlights Quest’s commitment to industry influence and leadership. Building relationships through these channels can open doors for collaborative opportunities and targeted outreach.

Technology & Data Integration Quest’s utilization of technologies like AWS, Tableau, and SuccessFactors points to a robust data infrastructure that can streamline reporting, analytics, and client engagement. Offering tailored technology integrations can add value for clients seeking improved operational insights.

Healthcare Market Trends Recent data on rising Fentanyl positivity rates and increased drug testing demand reflect evolving healthcare and workplace safety needs. Products and services that address these trends, such as enhanced drug screening and pharmacogenomics, present targeted sales opportunities to healthcare providers and employers.